A Standardized Nursing Intervention Protocol for HCT Patients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00951626 |
|
Recruitment Status :
Completed
First Posted : August 4, 2009
Last Update Posted : June 8, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Visiting patients at home to teach them about self care after a stem cell transplant may be more effective than standard therapy in improving quality of life.
PURPOSE: This clinical trial is studying home visits to see how well they work compared with standard therapy in treating patients undergoing donor stem cell transplant for hematologic cancer.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chronic Myeloproliferative Disorders Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Psychosocial Effects of Cancer and Its Treatment Therapy-related Toxicity | Behavioral: exercise intervention Behavioral: telephone-based intervention Dietary Supplement: dietary intervention Other: educational intervention Other: questionnaire administration Procedure: allogeneic bone marrow transplantation Procedure: allogeneic hematopoietic stem cell transplantation Procedure: assessment of therapy complications Procedure: peripheral blood stem cell transplantation Procedure: psychosocial assessment and care Procedure: quality-of-life assessment Procedure: standard follow-up care | Not Applicable |
OBJECTIVES:
Primary
- Test the effects of a Standardized Nursing Intervention Protocol (SNIP) on overall quality of life (QOL); physical, psychological, social, and spiritual well-being subscales; and functional status of patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT) at discharge, 3, 6, and 12 months post-hospitalization as compared to AHSCT patients who receive the usual care and attention control.
Secondary
- Test the effects of SNIP-AHSCT on time-to-first complication, total number of complications, and mortality across these groups of patients.
- Identify subgroups of patients who benefit most from the SNIP-AHSCT in relation to sociodemographic characteristics, disease and clinical factors, and transplant factors.
- Decompose the effect of the SNIP-AHSCT on QOL into direct and indirect effects.
OUTLINE: Patients are randomized to 1 of 2 treatment groups.
- Group 1: Patients receive home teaching visits on medical aspects of self care, monitor and respond to signs and symptoms of infections, recommended exercise and nutrition program, relevant literature on bone marrow transplantation, diet, nutrition, and a variety of resources at 1, 2, and 3 months after hospital discharge. Patients also receive telephone-reinforcement calls monthly in months 4-12, and have a 24-hour telephone availability throughout the study. Patients complete the City of Hope quality of life questionnaires on physical, psychological, social, and spiritual well-being, and physical functional status at discharge, and then at 3, 6, and 12 months after hospitalization.
- Group 2: Patients receive usual medical care and attention at discharge, and then at 3, 6, and 12 months after hospitalization. Patients also have a hot-line availability throughout the study.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 282 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Health Services Research |
| Official Title: | A Standardized Nursing Intervention Protocol for HCT Patients |
| Study Start Date : | September 2005 |
| Actual Primary Completion Date : | September 2011 |
| Actual Study Completion Date : | September 2011 |
- Behavioral: exercise intervention
Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.
Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge.
- Behavioral: telephone-based intervention
Those on the Standard Nursing Intervention Program will receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.
For those on the Usual Care plus Attention Control program, the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant.
- Dietary Supplement: dietary intervention
Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.
Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge.
- Other: educational intervention
Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.
Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge.
- Other: questionnaire administration
For both groups of participants, administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
- Procedure: allogeneic bone marrow transplantation
Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic bone marrow transplant.
- Procedure: allogeneic hematopoietic stem cell transplantation
Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
- Procedure: assessment of therapy complications
Collected throughout the 12 month study period
- Procedure: peripheral blood stem cell transplantation
Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
- Procedure: psychosocial assessment and care
Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge. They will also receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.
- Procedure: quality-of-life assessment
For both groups of participants, questionnaires administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
- Procedure: standard follow-up care
Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge. Also the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant.
- Overall quality of life (physical, psychological, social, and spiritual well-being) [ Time Frame: Baseline (discharge from hospital following Hematopoietic Cell Transplant) and 3, 6, and 12 months post baseline ]
- Functional status [ Time Frame: Baseline (discharge from hospital following Hematopoietic Cell Transplant) and 3, 6, and 12 months post baseline ]
- Time-to-first complication [ Time Frame: Baseline (discharge from hospital following Hematopoietic Cell Transplant) and 3, 6, and 12 months post baseline ]
- Total number of complications [ Time Frame: Baseline (discharge from hospital following Hematopoietic Cell Transplant) and 3, 6, and 12 months post baseline ]
- Mortality [ Time Frame: Baseline (discharge from hospital following Hematopoietic Cell Transplant) and 3, 6, and 12 months post baseline ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
- Diagnosis of a hematologic cancer (e.g., leukemia or lymphoma)
- Scheduled for a single allogeneic bone marrow or peripheral blood stem cell transplantation
PATIENT CHARACTERISTICS:
- Living within a 50-mile radius of the City of Hope National Medical Center
- English-speaking
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior hematopoietic stem cell transplantation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00951626
| United States, California | |
| City of Hope Comprehensive Cancer Center | |
| Duarte, California, United States, 91010-3000 | |
| Principal Investigator: | Marcia Grant, RN, DNSc, FAAN | City of Hope Comprehensive Cancer Center |
| Responsible Party: | City of Hope Medical Center |
| ClinicalTrials.gov Identifier: | NCT00951626 |
| Other Study ID Numbers: |
05081 R01CA107446 ( U.S. NIH Grant/Contract ) P30CA033572 ( U.S. NIH Grant/Contract ) CHNMC-05081 CDR0000643265 ( Registry Identifier: NCI PDQ ) |
| First Posted: | August 4, 2009 Key Record Dates |
| Last Update Posted: | June 8, 2015 |
| Last Verified: | June 2015 |
|
psychosocial effects of cancer and its treatment therapy-related toxicity stage III adult Burkitt lymphoma stage III adult diffuse large cell lymphoma stage III adult diffuse mixed cell lymphoma stage III adult diffuse small cleaved cell lymphoma stage III adult Hodgkin lymphoma stage III adult immunoblastic large cell lymphoma stage III adult lymphoblastic lymphoma stage III grade 1 follicular lymphoma stage III grade 2 follicular lymphoma stage III grade 3 follicular lymphoma stage III mantle cell lymphoma stage III marginal zone lymphoma stage III small lymphocytic lymphoma |
stage IV adult Burkitt lymphoma stage IV adult diffuse large cell lymphoma stage IV adult diffuse mixed cell lymphoma stage IV adult diffuse small cleaved cell lymphoma stage IV adult Hodgkin lymphoma stage IV adult immunoblastic large cell lymphoma stage IV adult lymphoblastic lymphoma stage IV grade 1 follicular lymphoma stage IV grade 2 follicular lymphoma stage IV grade 3 follicular lymphoma stage IV mantle cell lymphoma stage IV marginal zone lymphoma stage IV small lymphocytic lymphoma recurrent adult Burkitt lymphoma recurrent adult diffuse large cell lymphoma |
|
Lymphoma Leukemia Neoplasms Multiple Myeloma Neoplasms, Plasma Cell Preleukemia Plasmacytoma Myelodysplastic Syndromes Myeloproliferative Disorders Myelodysplastic-Myeloproliferative Diseases Syndrome Neoplasms by Histologic Type Lymphoproliferative Disorders Lymphatic Diseases |
Immunoproliferative Disorders Immune System Diseases Disease Pathologic Processes Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Bone Marrow Diseases Precancerous Conditions |

